Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 81, Issue 3, 1996, Pages 291-296

  Epstein, Joel B ^a,b,c,d,f   Ransier, Alison ^b   Lunn, Ruth ^a   Chin, Edward ^e   Jacobson, Jed J ^e   Le, Nhu ^a   Reece, Donna ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b Vancouver Hospital   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^f School of Dentistry ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; DENTAL CARE; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MYELOID LEUKEMIA; NONPARAMETRIC TEST; PREMEDICATION; THRUSH;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; BONE MARROW TRANSPLANTATION; CANDIDIASIS, ORAL; DENTAL CARE FOR CHRONICALLY ILL; DRUG RESISTANCE, MICROBIAL; FEMALE; FLUCONAZOLE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PREMEDICATION; STATISTICS, NONPARAMETRIC;

EID: 0030097882     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-2104(96)80328-3     Document Type: Article

References (70)

1. Dreizen S, Bodey GP, Valdivieso M. Chemotherapy: associated oral infections in adults with solid tumors. ORAL SURG ORAL MED ORAL PATHOL 1983;55:113-20.
2. Barren AP. A long-term prospective clinical study of oral complications during conventional chemotherapy for acute leukemia. ORAL SURG ORAL MED ORAL PATHOL 1987;63:313-6.
3. Dreizen S, Bodey GP, McCredie KB, et al. Orofacial aspergillosis in acute leukemia. ORAL SURG ORAL MED ORAL PATHOL 1985;59:499-504.
4. Bodey GP. Candidiasis in cancer patients. Am J Med 1984;77:13-9.
5. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.
6. DeGregorio MW, Lee WMF, Ries CA. Candida infection in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship with oropharyngeal and systemic candidiasis. Cancer 1982;50:2780-4.
7. Epstein JB. Infection prevention in BMT and radiation patients. J Natl Cancer Inst 1990;9:73-85.
8. Hann IM, Prentice HG, Corringham R, et al. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1982;1:826-9.
9. Thurmond JM, Brown AT, Sims RE, Ferretti GA, et al. Oral Candida albicans in bone marrow transplant patients given chlorhexidine rinses: occurrence and susceptibilities to the agent. ORAL SURG ORAL MED ORAL PATHOL 1991;72:291-5.
10. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
11. Denning DS, Donnelly JP, Hellreigel KP, et al. Antifungal prophylaxis during neutropenic or allogenic bone marrow transplantation: what is the state of the art? Chemotherapy 1992;38(suppl 1):43-9.
12. Meunier F. Prevention of mycosis in immunocompromised patients. Rev Infect Dis 1987;9:408-16.
13. Young LS. The outlook for antifungal prophylaxis in the compromised host. J Antimicrob Chemother 1982;9:338-340.
14. Quintiliani R, Owens NJ, Quericia RA, et al. Treatment and prevention of oropharyngeal candidiasis. Am J Med 1984;77:34-8.
15. Cliff RA. Candidiasis in the transplant patient. Am J Med 1984;77:34-8.
16. Meunier-Carpentier F, Kiehn T, Armstrong D. Fungemia in the immunocompromised host: changing patterns, antigenemia, high mortality. Am J Med 1981;71:363-70.
17. Bender JF, Schimpff SC, Young VM, et al. A comparative trial of tobramycin vs. gentamicin in combination with vancomycin and nystatin for alimentary tract suppression in leukemic patients. Eur J Cancer 1979;15:35-44.
18. Barrett AP. Evaluation of nystatin in prevention and elimination of oropharyngeal Candida in immunosuppressed patients. ORAL SURG ORAL MED ORAL PATHOL 1984;58:148-51.
19. Berkowitz RJ, Crock J, Strickland R, et al. Oral complications associated with bone marrow transplantation in a pediatric population. Am J Pediatr Hematol Oncol 1983;5:53-7.
20. Williams C, Whitehouse JMA, Lister TA, et al. Oral anticandidal prophylaxis in patients undergoing chemotherapy for acute leukemia. Med Pediatr Oncol 1977;3:275-80.
21. Meunier-Carpentier F. Prophylaxis of fungal infections in neutropenic cancer patients. Schweiz Med Wochenschr 1983;133(suppl 14):15-9.
22. Meunier-Carpentier F, Cruciani M, Klastersky J. Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. Eur J Cancer Clin Oncol 1983;19:43-8.
23. Carpentiere V, Haggard ME, Lockhart LH, et al. Clinical experience in prevention of candidiasis by nystatin in children with acute lymphocytic leukemia. J Pediatr 1978;92:593-5.
24. Brinkner H. Treatment of oral candidiasis in debilitated patients with miconzone: a new potent antifungal drug. Scand J Infect Dis 1976;8:117-20.
25. Pizzuto J, Conte G, Ambriz R, et al. Nystatin prophylaxis in leukemia and lymphoma. N Engl J Med 1978;298:279-80.
26. Williams CJ. Nystatin prophylaxis in leukemia and lymphoma. N Engl J Med 1978;298:853.
27. Hargardon MT, Yang VM, Schimpff SC, et al. Selective suppression of alimentary tract microbial flora as prophylaxis during granulocytopenia. Antimicrob Agents Chemother 1981;20:620-4.
28. Jones PG, Kauffman CA, McAuliffe LS, Liepman MK, Bergman AG. Efficacy of ketoconazole versus nystatin in prevention of fungal infections in neutropenic patient. Arch Intern Med 1984;144:549-51.
29. Donnelly JP, Starke ID, Galton DA, Catovsky D, Goldman JM, Darrell JN. Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukemia. J Hosp Infect 1984;5:83-91.
30. De Vreis-Hospers HG, Mulder NH, Sleijfer DT, Van Sorene HKF. The effects of amphotericin B lozenges on the presence and number of Candida cells in the oropharynx of neutropenic leukemia patients. Infection 1982;10:71-5.
31. McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouth rinse regimen. ORAL SURG ORAL MED ORAL PATHOL 1985;60:275-80.
32. Ferretti GA, Hansen IA, Whittenburg K, Brown AT, Lillich TT, Ash RC. Therapeutic use of chlorhexidine in bone marrow transplant patients: case studies. ORAL SURG ORAL MED ORAL PATHOL 1987;63:683-7.
33. Ferretti GA, Ash RC, Brown AT, Parr MD, Romond EH, Lillich TT. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 1988;3:483-93.
34. Ferretti GA, Largent BM, Ash RC, Kapken A, Brown AT, Lillich TT. Chlorhexidine for prophylaxis against oral infection and associated complications in patients receiving bone marrow transplants. J Am Dent Assoc 1987;114:461-7.
35. Epstein JB, Vickars L, Spinelli J, Reece, D. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. ORAL SURG ORAL MED ORAL PATHOL 1992;73:682-9.
36. Weisdorf DJ, Bostrom B, Raether D, et al. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and effect of chlorhexidine mouth rinse. Bone Marrow Transplant 1989;4:89-95.
37. Wahlin YB. Effects of chlorhexidine mouthrinse on oral health in patients with acute leukemia. ORAL SURG ORAL MED ORAL PATHOL 1989;68:279-87.
38. Meunier F. Prevention of mycoses in immunocompromised patients. Rev Infect Dis 1987;9:408-16.
39. Alsip S, Stamm AM, Dismulces WE. Ketoconazole, miconazole and other imidazoles. In: Saroal GA, Davies SF, eds. Fungal disease of the lung. Orlando, Florida: Grine-Stratton, 1986:335-76.
40. Kostiala I, Kostiala AAI, Klonen E, Valtonen VV, Vuopio P. Comparison of clotrimazole and chlorhexidine in the topical treatment of acute fungal stomatitis in patients with hematologic malignancies. Curr Ther Res 1982;31:752-63.
41. Owens NJ, Nightingale CH, Schweizer RT, Schauer PK, Dekker PT, Quintiliam R. Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med 1984;144:260-3.
42. Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized prospective multicenter study of oral fluconazole versus clotrimazole troches. AIDS 1993;6:1311-6.
43. Dismukes WE, Cloud G, Bowles C, et al. Treatment of blastomycosis and histoplasmosis with ketoconazole. Ann Intern Med 1985;103:861-72.
44. Shepp DN, Klosterman A, Siegel MS, Meyers JD. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J Infect Dis 1985;152:1257-63.
45. Walsh TJ, Lee J, Mechinaud F, et al. Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granuocytopenic hosts. Rev Infect Dis 1990;12(suppl 3):307-17.
46. Saeg MS, Dismukes NE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother 1988;32:1-8.
47. Anaissie E, Bodey GP, Kantarjian H, et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991;91:142-50.
48. Shaw JTB, Tarbit MH, Troke PF. Cytochrone p-450 mediated sterol synthesis and metabolism: differences in sensitivity to fluconazole and other azoles. In: Fromling RA, ed. Recent trends in the discovery, development, and evaluation of antifungal agents. Barcelona: JR Prous Publing, 1987:125-39.
49. Darwazeh AMG, Lamey P-J, Lewis MAO, Samaranayake LP. Systemic fluconazole therapy and in vitro adhesion of Candida albicans to human buccal epithelial cells. J Oral Pathol Med 1991;20:17-9.
50. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
51. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluations of UK-49, 858, or metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 1985;28:648-53.
52. Kruger HU, Schuler Y, Zimmerman R, Ehninger G. Absence of significant interaction of fluconazole with cyclosporin. J Antimicrob Chemother 1989;24:781-6.
53. Veraillie C, Weisdorf D, Haake R, Hostitter M, Ramsay N, McGlave P. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991;8:177-84.
54. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11.
55. Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia: multicentre study group. J Antimicrob Chemother 1993;31:973-84.
56. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.
57. Wingard JR. Oral complications of cancer therapies: infectious and non-infectious systemic consequences. NCI Monogr 1990;9:21-6.
58. Epstein JB, Freilich MM, Le ND. Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. ORAL SURG ORAL MED ORAL PATHOL 1993;76:169-74.
59. Epstein JB, Pearsall NN, Truelove EL. Oral candidiasis: effects of antifungal therapy upon clinical signs and symptoms, salivary antibody, and mucosal adherence of Candida albicans. ORAL SURG ORAL MED ORAL PATHOL 1981;51:32-6.
60. Lehamann EL. Non-parametrics: statistical methods based on ranks. New York: McGraw Hill, 1975:205-10.
61. Donnelly JP, Muus P, Horrevorts AM, Sauerwein RA, De Pauw BE. Failure of clindamycin to influence the course of severe oromucositis associated with streptococcal bacteraemia in allogeneic bone marrow transplant recipients. Scand J Infect Dis 1993;25:43-50.
62. Donnelly JP, Muus P, Schattenberg A, De Witte T, Horrevorts A, DePauw BE. A scheme for daily monitoring of oral mucositis in allogenic BMT recipients. Bone Marrow Transplant 1992;9:409-13.
63. Ferretti GA, Raybould TP, Brown AT, et al. Chlorhexidine prophylaxis for chemotherapy and radiotherapy-induced stomatitis: a randomized double-blind trial. ORAL SURG ORAL MED ORAL PATHOL 1990;69:331-8.
64. Fan-Harvard P, Capano D, Smith SM, Mangia A, Eng RHK, Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimucrob Agents Chemother 1991;35:2302-5.
65. Gallagher PJ, Bennett DE, Henman MC, et al. Reduced azole susceptibility of oral isolates of Candida albicans from HIV-positive patients and a derivate exhibiting colony morphology variation. J Gen Microbiol 1992;138:1901-11.
66. Heinic GS, Stevens DA, Greenspan D, et al. Fluconazole-resistant Candida in AIDS patients: report of two cases. ORAL SURG ORAL MED ORAL PATHOL 1993;76:711-5.
67. Galgiani JN. Antifungal susceptibility tests. Antimicrob Agents Chemother 1987;31:1867-70.
68. Cap J, Mojzesova A, Kayserova E, et al. Fluconazole in children: first experience with prophylaxis in chemotherapy-induced neutropenia in pediatric patients with cancer. Chemotherapy 1993;39:438-42.
69. EORTC international antimicrobial therapy cooperative group: empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-72.
70. Schaison G, Baruchel A, Ariel G. Prevention of gram positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic patients. Br J Hematol 1990;76(suppl 2):24-6.